Otros idiomas Personalis, Inc.

Acciones

PSNL

US71535D1063

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 03/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,54 ^USD	-3,75 %		+21,74 %	-26,67 %

30/04	PERSONALIS, INC. : recomendación de compra de Lake Street	ZM
26/03	Personalis, Inc. Anuncia una publicación que valida la prueba NeXT Personal para la detección ultrasensible de MRD y la monitorización de la respuesta al tratamiento del cáncer	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Personalis to Announce First Quarter 2024 Financial Results	24/04
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference	28/03
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting	28/03
Personalis Announces Publication Validating NeXT Personal Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring	27/03
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring	26/03
Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring	26/03
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	20/03
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	19/03
Personalis: Q4 Earnings Snapshot	28/02
Personalis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Earnings Flash (PSNL) PERSONALIS Reports Q4 Revenue $19.7M, vs. Street Est of $19.3M	28/02
Personalis Reports Fourth Quarter and Full Year 2023 Financial Results	28/02
Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	28/02
Personalis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results	14/02
Personalis to Participate at Upcoming Investor Conferences	31/01
Personalis to Offer ClearNote's Epigenomic Platform in Partnership	30/01
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology	30/01
Personalis, Inc. and ClearNote Health, Inc. Announce Partnership to Advance Epigenomic Technology	30/01
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	18/01

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Personalis, Inc.

Acciones

PSNL

US71535D1063

Otros idiomas

Filtros